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Abstract: Bleeding severity in patients undergoing percutaneous coronary intervention (PCI),
defined by the Bleeding Academic Research Consortium (BARC), portends adverse prognosis.
We analysed data from 37,866 Australian patients undergoing PCI enrolled in the Victorian Cardiac
Outcomes Registry (VCOR), and investigated the association between increasing BARC severity and
in-hospital and 30-day major adverse cardiac and cerebrovascular events (MACCE) (a composite
of mortality, myocardial infarction, stent thrombosis, target vessel revascularisation, or stroke).
Independent predictors associated with major bleeding (BARC groups 3&5), and MACCE were
also assessed. There was a stepwise increase in in-hospital and 30-day MACCE with greater
severity of bleeding. Independent predictors of bleeding included female sex (Odds Ratio (OR)
1.34), age (OR 1.02), fibrinolytic therapy (OR 1.77), femoral access (OR 1.51), and ticagrelor (OR 1.42),
all significant at the p < 0.001 level. Following adjustment of clinically important variables, BARC 3&5
bleeds (OR 4.37) were still predictive of cumulative in-hospital and 30-day MACCE. In conclusion,
major bleeding is an uncommon but potentially fatal PCI complication and was independently
associated with greater MACCE rates. Efforts to mitigate the occurrence of bleeding, including radial
access and judicious use of potent antiplatelet therapies, may ameliorate the risk of short-term adverse
clinical outcomes.
Keywords: Bleeding Academic Research Consortium (BARC); bleeding; percutaneous coronary
intervention (PCI); clinical outcomes; major adverse cardiac and cerebrovascular events (MACCE)
1. Introduction
The cornerstone of treatment for patients presenting with acute coronary syndromes (ACS) is timely
mechanical revascularisation with percutaneous coronary intervention (PCI) and potent antiplatelet
pharmacotherapy. Bleeding is a recognised and important complication of PCI, and there is a significant
body of evidence that associates peri-procedural (i.e., peri-PCI) bleeding with poor clinical outcomes,
including an increased risk of both short- and long-term mortality [1–3]. Major bleeding complications
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occur at either the arterial access site, commonly the femoral and radial artery, or from non-access
site sources (predominantly gastrointestinal, intracranial, and retroperitoneal) [3]. Numerous studies
have demonstrated that the femoral approach is independently associated with worse major bleeding
outcomes [1,4–8]. Other major published predictors of bleeding include, but are not limited to, older
age, female sex, low body mass index (BMI), renal impairment, and the use of potent antiplatelet
agents and fibrinolytic therapy [9,10].
However, there is paucity of data in contemporary Australian practice pertinent to the clinical
impact of PCI-related bleeding. Therefore, the primary objective of this study was to investigate the
association between bleeding severity in PCI and short-term clinical outcomes in a large Australian
multicentre registry of an all-comers population. This study used a standardised and robust model
for defining bleeding, developed by the Bleeding Academic Research Consortium (BARC) [11].
Furthermore, this study secondarily investigated the effect of baseline and procedural characteristics
on the severity of BARC-defined bleeding.
2. Methods
2.1. Study Population
We retrospectively analysed patient data from the Victorian Cardiac Outcomes Registry (VCOR)
between January 2014 and December 2017. The VCOR is a state-wide population-based clinical quality
registry that collects data related to PCI procedures and outcomes from all 30 public and private
hospitals around Victoria. It is coordinated by Monash University in conjunction with the Department
of Health and Human Services, and the Victorian Cardiac Clinical Network. The registry records
on standardised case reports form PCI-related data, including patient demographics, procedural
characteristics, and clinical outcomes and complications, with a 30-day follow-up period. Data are
entered by trained hospital staff in real time as the patient progresses through a hospital admission,
and data entry personnel are registered with VCOR. Participant data are prospectively entered into
the VCOR unless they choose to ‘opt-out’. Regular auditing activities by the central registry ensures
data integrity.
2.2. Definitions
The primary outcome was 30-day major adverse cardiac and cerebrovascular events (MACCE),
a composite of clinical events occurring in-hospital and up to 30-days post discharge. MACCE
was defined as all-cause mortality, new or recurrent myocardial infarction (MI) or stent thrombosis,
target vessel revascularisation, or nonfatal stroke. Patients with missing 30-day MACCE data were
excluded from the analysis.
ACS was defined as a composite of ST-elevation myocardial infarction (STEMI), non-STEMI
(NSTEMI), and unstable angina (chest pain at rest with unchanged cardiac biomarkers and ECG).
Stable angina as an indication for PCI was defined as chest pain syndrome associated with exertion
due to inducible myocardial ischaemia. Coronary lesion type was defined according to the American
College of Cardiology (ACC) and the American Heart Association (AHA) classification as type A,
type B1, type B2, and type C in order of increasing complexity [12].
New renal impairment was defined as an increase of ≥25% or ≥44.2 mmol/L in serum creatinine
up to 5 days after the index PCI, when compared to baseline. Cardiogenic shock was defined as
a sustained (>30 min) episode of hypotension (systolic blood pressure (SBP) < 90 mmHg), or the use of
vasopressors to maintain the SBP > 90 mmHg, together with evidence of end-organ hypoperfusion
(e.g., altered mentation, reduced urine output) and increased left ventricular filling pressures, such as
pulmonary congestion. MI was defined as new elevation of cardiac biomarkers ≥ 20% compared
to baseline levels, as well as one of the following: (1) ST-segment elevation distinct from the initial
ischaemic event, (2) symptoms of myocardial ischaemia lasting ≥ 20 min, (3) development of new
Q-waves in 2 or more contiguous leads, (4) angiographic evidence of flow limitation, and (5) evidence
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of new abnormalities in regional wall motion on imaging [13]. Stroke was defined as an ischaemic or
haemorrhagic event of the brain during the initial PCI or the course of the admission, manifesting as
a persistent neurological deficit. Anti-thrombotic therapy includes unfractionated heparin and low
molecular weight (LMW) heparin.
In-hospital and outcomes up to 30 days were recorded, including rehospitalisation, readmission, MI,
stent thrombosis, bleeding event, stroke, MACCE, and major adverse cardiac events (MACE), which was
defined as MACCE minus stroke. These were verified from medical records, patients, and/or their
primary care physician.
The BARC bleeding criteria were divided into three categories: type 0 (no bleed), type 1&2 (‘minor’
bleed), and type 3&5 (clinically significant or ‘major’ bleed) [11]. A bleeding event as defined in VCOR
refers to a new bleeding event either during the cardiac catheter lab visit, after the lab visit, or any
subsequent lab visits but prior to discharge. The timing of bleeding events is, therefore, between PCI
and the date of discharge, i.e., ‘in-hospital bleeding’. In case of BARC 5 fatal bleeding, this refers to
a bleeding event that directly causes death with no other explainable cause. BARC type 4 bleeds refer to
PCI patients who underwent coronary artery bypass graft (CABG) surgery and had a subsequent bleed.
These bleeds are not directly associated with the PCI procedure and were, therefore, excluded from our
analysis. However, patients requiring CABG surgery (as a potentially emergent complication of PCI)
without BARC 4 bleeds were not excluded. These patients may have experienced PCI-related bleeding
complications, affecting MACCE outcomes independent of their CABG surgery. The individual
definition and criteria comprising the BARC types are detailed in the Appendix A.
2.3. Statistics
Continuous variables are presented as mean± standard deviation (SD) or median with interquartile
range (IQR), and categorical variables are presented as frequencies and percentages. Differences between
the 3 BARC groups were evaluated using one-way analysis of variance (ANOVA) or Kruskal–Wallis
test for continuous variables, and a chi-square test for categorical variables. p-values were calculated
to demonstrate statistical significance between any two of the BARC groups. If significant (p < 0.05),
post-hoc pairwise comparisons were conducted to evaluate which two BARC groups were different
(i.e., BARC 0 versus BARC 1&2, BARC 1&2 versus BARC 3&5, and/or BARC 0 versus BARC 3&5).
The independent effect of BARC-defined bleeding and other clinically relevant characteristics
on cumulative in-hospital and 30-day MACCE (the primary outcome) was evaluated using a logistic
regression model. Variables included in the multivariable analysis were the 3 BARC categories,
characteristics that were clinically significant in the univariate analysis, as well as pre-defined
variables that represented well-described predictors of bleeding, which included age, female sex, BMI,
procedural creatinine, diabetes, peripheral vascular disease (PVD), out-of-hospital cardiogenic shock
(OHCA), cardiogenic shock, fibrinolytic therapy, administration of glycoprotein IIb/IIIa inhibitors
(GPI), and mode of vascular access [14–17]. The effect of baseline patient and procedural characteristics
on the severity of BARC-defined bleeding were also assessed using logistic regression. All tests were
2-tailed and assessed at the 5% significance level. No adjustments for multiple comparisons were made.
Yearly rates for mode of vascular access, BARC-defined bleeding, in-hospital MACCE,
and cumulative in-hospital and 30-day MACCE from 2014 to 2017, among STEMI patients and
ACS patients other than STEMI, were also shown for descriptive purposes.
3. Results
Of 37,913 patients enrolled in the VCOR from January 2014 to December 2017, we analysed the data
of 37,866 patients (n = 47 excluded for BARC 4 bleeding and missing 30-day MACCE data). The mean
age was 66 years and 76.5% were male. Of 37,886 patients, 91.2% (n = 34,555) experienced no bleeding
(BARC 0), 7.9% (n = 3007) experienced a minor bleed (BARC 1&2), and 0.9% (n = 324) experienced
a clinically significant major bleed (BARC 3&5). Notable baseline characteristics in this all-comers
population included diabetes mellitus requiring medication prevalence of 22%, history of prior PCI
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(32.6%), history of prior CABG (7.7%), and moderate to severe heart failure (13.2%), defined by the
New York Heart Association (NYHA) as left ventricular ejection fraction (LVEF) < 45%.
Baseline patient characteristics of the three BARC groups are presented in Table 1. Compared to
the BARC 0 group, more patients with BARC 1&2 bleeds and BARC 3&5 bleeds were female, older,
and had a lower BMI (all p < 0.001). There were stepwise increases in BARC-defined bleeding among
patients with worsening renal impairment (estimated glomerular filtration rate (eGFR) < 60%) with
or without dialysis, those with moderate to severe LV systolic dysfunction, OHCA, cardiogenic
shock, in-hospital pre-procedural cardiac arrest, or were administered GPI, or fibrinolytic therapy
(all p < 0.001). In contrast, there were no significant differences between BARC groups in rates of
patients with diabetes, patients on chronic oral anticoagulant therapy, and patients administered
fibrinolytic therapy ≤ 24 h prior to PCI (p = not significant).
Table 1. Baseline clinical characteristics.
BARC 0 (n = 34,555) BARC 1&2 (n = 3007) BARC 3&5 (n = 324) p-Value
CLINICAL CHARACTERISTICS
Age—years, mean
± SD 65.7 (11.9) 67.6 (12.2) 68.4 (12.7) <0.001 *†
Male, n (% of
BARC) 26,637 (77.1%) 2117 (70.4%) 214 (66.0%) <0.001 *†
Female, n (% of
BARC) 7918 (22.9%) 890 (29.6%) 110 (34.0%) <0.001 *†
BMI (kg/m2), mean
± SD 28.9 (5.4) 28.3 (5.5) 27.7 (5.4) <0.001 *†
Diabetes mellitus
on medication, n
(%)
7599 (22.0%) 658 (21.9%) 72 (22.2%) 0.98
Diabetes on insulin,
n (%) 2602 (7.5%) 208 (6.9%) 31 (9.6%) 0.11
Diabetes on oral
medications, n (%) 4997 (14.5%) 450 (15.0%) 41 (12.7%) 0.11
Peripheral vascular
disease, n (%) 1230 (3.6%) 101 (3.4%) 22 (6.8%) 0.01 †‡
Cerebrovascular
disease, n (%) 1281 (3.7%) 119 (4.0%) 20 (6.2%) 0.051
Previous CABG, n
(%) 2645 (7.7%) 252 (8.4%) 14 (4.3%) 0.03 †‡
Previous PCI, n (%) 11,366 (32.9%) 913 (30.4%) 81 (23.1%) <0.001 *†‡
Chronic oral
anticoagulant
therapy, n (%)
2029 (5.9%) 183 (6.1%) 21 (6.5%) 0.80
eGFR <30, n (%) 838 (2.4%) 108 (3.6%) 28 (8.6%) <0.001 *†‡
eGFR 30–59, n (%) 5629 (16.3%) 652 (21.7%) 93 (28.7%) <0.001 *†‡
eGFR >60, n (%) 25,287 (73.2%) 2088 (69.4%) 185 (57.1%) <0.001 *†‡
Dialysis, n (%) 377 (1.1%) 54 (1.8%) 10 (3.1%) <0.001 *†
LVEF, n (%) - - - -
1 = Normal
function (>50%) 20,112 (58.2%) 1606 (53.4%) 126 (38.9%) <0.001 *†‡
2 = Mild
dysfunction/impairment
(45–50%)
5664 (16.4%) 557 (18.5%) 59 (18.2%) <0.001 *†‡
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Table 1. Cont.
BARC 0 (n = 34,555) BARC 1&2 (n = 3007) BARC 3&5 (n = 324) p-Value
CLINICAL CHARACTERISTICS
3 = Moderate
dysfunction/impairment
(35–44%)
3055 (8.8%) 290 (9.6%) 56 (17.3%) <0.001 *†‡
4 = Severe
dysfunction/impairment
(<35%)
1352 (3.9%) 182 (6.1%) 50 (15.4%) <0.001 *†‡
Out of Hospital
Cardiac Arrest, n
(%)
723 (2.1%) 116 (3.9%) 56 (17.3%) <0.001 *†‡
Cardiogenic shock,
n (%) 734 (2.1%) 123 (4.1%) 83 (25.6%) <0.001 *†‡
In-hospital
pre-procedure
cardiac arrest, n (%)
500 (1.4%) 77 (2.6%) 32 (9.9%) <0.001 *†‡
Pre-procedure
intubation, n (%) 536 (1.6%) 106 (3.5%) 61 (18.8%) <0.001 *†‡
Glycoprotein
IIb/IIIa inhibitors, n
(%)
3377 (9.8%) 452 (15.0%) 98 (30.2%) <0.001 *†‡
Anti-thrombotic
therapy, n (%) 30,588 (88.5%) 2757 (91.7%) 292 (90.1%) <0.001 *
Aspirin
pre-loading, n (%) 31,102 (90.0%) 2822 (93.8%) 288 (88.9%) <0.001 *‡
Thienopyridine
pre-loading, n (%) 14,891 (43.1%) 1176 (39.1%) 92 (28.4%) <0.001 *†‡
Ticagrelor
pre-loading, n (%) 13,237 (38.3%) 1402 (46.6%) 140 (43.2%) <0.001 *†
Fibrinolytic
therapy, n (%) 1000 (2.9%) 135 (4.5%) 27 (8.3%) <0.001 *†‡
Fibrinolytic
therapy ≤24 h prior
to PCI, n (%)
754 (2.2%) 110 (3.7%) 24 (7.4%) 0.09
Values are n (%) or mean ± standard deviation (SD), or median (interquartile range). p-values in bold are statistically
significant. ACS = acute coronary syndrome, BARC = Bleeding Academic Research Consortium, BMI = body mass
index, CABG = coronary artery bypass graft, eGFR = estimated glomerular filtration rate, LVEF = left ventricular
ejection fraction, PCI = percutaneous coronary intervention. * BARC 0 versus BARC 1&2. † BARC 0 versus BARC
3&5. ‡ BARC 1&2 versus BARC 3&5.
Procedural characteristics of patients in the 3 BARC groups are presented in Table 2. There were
stepwise increases in bleeding severity among patients who had PCI with femoral vascular access,
and an inverse relationship in bleeding severity was observed among patients with radial access
(both p < 0.001). The BARC 3&5 group had higher rates of STEMI presentations, left main coronary artery
(LMCA) involvement, coronary lesion type B2 and C, and the use of bare metal stents, and thrombus
aspiration devices, procedural intubation, and extracorporeal mechanical support (all p < 0.001).
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Table 2. Baseline procedural characteristics.
BARC 0 (n = 34,555) BARC 1&2 (n = 3007) BARC 3&5 (n = 324) p-Value
PROCEDURAL CHARACTERISTICS
Door-to-balloon
time (minutes),
median (IQR)
73.0 (46.0, 125.0) 74.0 (47.0, 125.0) 71.0 (47.0, 126.0) 0.76
Symptom-to-balloon
time (minutes),
median (IQR)
234.0 (152.0, 507.0) 246.5 (156.0, 541.0) 217.0 (146.0, 488.0) 0.28
PCI indication, n
(%) - - - -
1 = Early Primary
PCI for STEMI < 12
hours
5336 (15.4%) 574 (19.1%) 127 (39.2%) <0.001 *†‡
2 = Late Primary
PCI for STEMI 776 (2.2%) 105 (3.5%) 18 (5.6%) <0.001 *†‡
3 = Thrombolytics
for STEMI 971 (2.8%) 135 (4.5%) 27 (8.3%) <0.001 *†‡
4 = PCI post
cardiac arrest or
cardiogenic shock
(non-MI)
99 (0.3%) 14 (0.5%) 9 (2.8%) <0.001 *†‡
5 = PCI for ACS
other than STEMI 11,897 (34.4%) 1083 (36.0%) 89 (27.5%) <0.001 *†‡
6 = Stable angina 12,916 (37.4%) 925 (30.8%) 41 (12.7%) <0.001 *†‡
7 = Other 2560 (7.4%) 171 (5.7%) 13 (4.0%) <0.001 *†‡
Femoral
percutaneous entry,
n (%)
16,710 (48.4%) 1772 (58.9%) 218 (67.3%) <0.001 *†‡
Radial
percutaneous entry,
n (%)
17,789 (51.5%) 1232 (41.0%) 101 (31.2%) <0.001 *†‡
Intra-vascular
ultrasound, n (%) 334 (1.0%) 88 (2.9%) 7 (2.2%) <0.001 *†
Thrombus
aspiration device, n
(%)
1327 (3.8%) 165 (5.5%) 42 (13.0%) <0.001 *†‡
Fractional flow
reserve, n (%) 934 (2.7%) 72 (2.4%) 7 (2.2%) 0.51
Procedural
intubation
required, n (%)
262 (0.8%) 43 (1.4%) 34 (10.5%) <0.001 *†‡
Intra-aortic balloon
pump (IABP), n (%) 116 (0.3%) 22 (0.7%) 18 (5.6%) <0.001 *†‡
Extracorporeal
mechanical
support, n (%)
12 (0.0%) 3 (0.1%) 14 (4.3%) <0.001 †‡
Location of PCI, n
(%) - - - -
LAD artery 13,962 (40.4%) 1237 (41.1%) 148 (45.7%) 0.12
RCA 10,701 (31.0%) 997 (33.2%) 118 (36.4%) 0.006 *†
LCx artery 5383 (15.6%) 441 (14.7%) 38 (11.7%) 0.07
LMCA 600 (1.7%) 75 (2.5%) 17 (5.2%) <0.001 *†‡
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Table 2. Cont.
BARC 0 (n = 34,555) BARC 1&2 (n = 3007) BARC 3&5 (n = 324) p-Value
PROCEDURAL CHARACTERISTICS
Graft vessel 668 (1.9%) 75 (2.5%) 3 (0.9%) 0.042 *
Other: PCI on any
other vessel 7349 (21.3%) 564 (18.8%) 58 (17.9%) 0.002 *
Coronary lesion
type, n (%) total - - - -
Type A 3788 (11.0%) 378 (12.6%) 29 (9.0%) 0.013 *
Type B1 12,977 (37.6%) 1211 (40.3%) 93 (28.7%) <0.001 *†‡
Type B2/C 20,031 (58.0%) 1650 (54.9%) 225 (69.4%) <0.001 *†‡
Stent thrombosis, n
(%) 361 (1.0%) 36 (1.2%) 16 (4.9%) <0.001 †‡
Type of stent(s), n
(%) total - - - -
None 2143 (6.2%) 218 (7.2%) 47 (14.5%) <0.001 †‡
Bare metal stent 3696 (10.7%) 310 (10.3%) 64 (19.8%) <0.001 †‡
Drug eluting stent 28,230 (81.7%) 2441 (81.2%) 209 (64.5%) <0.001 †‡
Type of balloon(s)
used, n (%) total - - - -
No balloon 32,400 (93.8%) 2794 (92.9%) 279 (86.1%) <0.001 †‡
Plain balloon 1954 (5.7%) 194 (6.5%) 44 (13.6%) <0.001 †‡
Drug eluting
balloon 206 (0.6%) 21 (0.7%) 1 (0.3%) 0.62
Multivessel PCI, n
(%) 2037 (5.9%) 181 (6.0%) 30 (9.3%) 0.038 †‡
Values are n (%) or mean ± SD, or median (interquartile range). P-values in bold are statistically significant.
ACS = acute coronary syndrome, BARC = Bleeding Academic Research Consortium, LAD = left anterior descending,
LCx = left circumflex, LMCA = left main coronary artery, MI = myocardial infarction, PCI = percutaneous coronary
intervention, RCA = right coronary artery, STEMI = ST-elevation myocardial infarction. * BARC 0 versus BARC
1&2. † BARC 0 versus BARC 3&5. ‡ BARC 1&2 versus BARC 3&5.
In-hospital outcomes and outcomes up to 30 days (events recorded from day of discharge to day
30 post discharge) within the three BARC groups are presented in Table 3. There was an increase
in adverse in-hospital outcomes with increasing severity of BARC-defined bleeding, including but
not limited to increased length of hospital stay, new renal impairment, cardiogenic shock, recurrent
MI, stroke, MACE, MACCE, and mortality (all p < 0.001). For example, in-hospital MACCE occurred
in 30.9% of patients who had BARC 3&5 bleeding, compared to 5.6% of patients who had BARC
1&2 bleeding and 2.7% of patients who had no bleeds (all p < 0.001). At 30-day follow-up, there
was a graded increase in incidence of new heart failure, and 30-day MACE, MACCE, and mortality,
with increasing severity of bleeding (all p < 0.05). There were also more rehospitalisations among
patients with BARC 3&5 bleeding compared to patients who had BARC 1&2 bleeding or BARC 0
bleeding (p < 0.001).
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Table 3. In-hospital outcomes and outcomes up to 30 days.
BARC 0 BARC 1&2 BARC 3&5 p-Value
IN-HOSPITAL OUTCOMES
Length of stay
(days), mean ± SD 2.0 (1.0, 4.0) 3.0 (1.0, 5.0) 8.5 (5.0, 16.5) <0.001 *†‡
New renal
impairment, n (%) 668 (1.9%) 169 (5.6%) 82 (25.3%) <0.001 *†‡
Planned CABG, n
(%) 94 (0.3%) 24 (0.8%) 10 (3.1%) 0.005 †‡
TVR (CABG), n (%) 129 (0.4%) 25 (0.8%) 26 (8.0%) 0.39
Definite stent
thrombosis n (%) 62 (0.2%) 17 (0.6%) 3 (0.9%) <0.001 *†‡
Probable stent
thrombosis n (%) 24 (0.1%) 5 (0.2%) 2 (0.6%) <0.001 *†‡
Possible stent
thrombosis n (%) 9 (0.0%) 3 (0.1%) 3 (0.9%) <0.001 *†‡
No stent
thrombosis n (%) 34,460 (99.7%) 2982 (99.2%) 316 (97.5%) <0.001 *†‡
Stroke, n (%) - - - -
Haemorrhagic 11 (0.0%) 7 (0.2%) 17 (5.2%) <0.001 †‡
Ischaemic 56 (0.2%) 12 (0.4%) 5 (1.5%) <0.001 †‡
Mortality, n (%) 555 (1.6%) 89 (3.0%) 73 (22.5%) <0.001 *†‡
MACE, n (%) 882 (2.6%) 156 (5.2%) 88 (27.2%) <0.001 *†‡
MACCE, n (%) 932 (2.7%) 168 (5.6%) 100 (30.9%) <0.001 *†‡
OUTCOMES UP TO 30 DAYS (EXCLUDING IN-HOSPITAL OUTCOMES)
New heart failure,
n (%) 261 (0.8%) 54 (1.8%) 12 (3.7%) <0.001 *†‡
30-day myocardial
infarction, n (%) 150 (0.4%) 17 (0.6%) 1 (0.3%) <0.001 *†‡
30-day definite
stent thrombosis, n
(%)
82 (0.2%) 7 (0.2%) 1 (0.3%) <0.001 *†‡
30-day probable
stent thrombosis, n
(%)
9 (0.0%) - 2 (0.6%) <0.001 *†‡
30-day possible
stent thrombosis, n
(%)
12 (0.0%) 4 (0.1%) - <0.001 *†‡
30-day stroke, n (%) - - - -
1 = Haemorrhagic 9 (0.0%) 3 (0.1%) - 0.36
2 = Ischaemic 30 (0.1%) 2 (0.1%) - 0.36
Rehospitalisation,
n (%) 4339 (12.6%) 368 (12.2%) 51 (15.7%) <0.001 *†‡
Cardiac
readmission, n (%) 2941 (8.5%) 230 (7.6%) 19 (5.9%) <0.001 *†‡
J. Clin. Med. 2020, 9, 1426 9 of 17
Table 3. Cont.
BARC 0 BARC 1&2 BARC 3&5 p-Value
IN-HOSPITAL OUTCOMES
30-day Mortality, n
(%) 169 (0.5%) 22 (0.7%) 7 (2.2%) <0.001 *†‡
Cardiac Mortality,
n (%) 72 (0.2%) 10 (0.3%) 3 (0.9%) 0.54
30-day MACE, n
(%) 438 (1.3%) 47 (1.6%) 8 (3.4%) 0.007 *†‡
30-day MACCE, n
(%) 472 (1.4%) 51 (1.8%) 7 (3.1%) 0.03 *†‡
Values are n (%) or mean ± SD, or median (interquartile range). p-values in bold are statistically significant.
CABG = coronary artery bypass graft, MACE = major adverse cardiac events, MACCE = major adverse cardiac or
cerebrovascular events, PCI = percutaneous coronary intervention, TVR = target vessel revascularization, TLR =
target lesion revascularization. * BARC 0 versus BARC 1&2. † BARC 0 versus BARC 3&5. ‡ BARC 1&2 versus
BARC 3&5.
Medications prescribed at discharge are presented in Table 4. Patients who experienced BARC 3&5
bleeding were prescribed fewer antiplatelet agents including aspirin, thienopyridine, and ticagrelor,
as well as beta-blockers, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
blockades (ARBs), and statins, compared to patients who experienced no bleeding (all p < 0.001).
However, there were more patients in the BARC 3&5 cohort prescribed oral anticoagulants (p < 0.001).
Table 4. Medications at discharge from hospital.
BARC 0 BARC 1&2 BARC 3&5 p-Value
Aspirin, n (%) 33,014 (95.5%) 2841 (94.5%) 232 (71.6%) <0.001 †‡
Thienopyridine, n (%) 17,868 (51.7%) 1370 (45.6%) 119 (36.7%) <0.001 *†‡
Ticagrelor, n (%) 15,470 (44.8%) 1468 (48.8%) 95 (29.3%) <0.001 *†‡
Beta blockers, n (%) 23,390 (67.7%) 2213 (73.6%) 198 (61.1%) <0.001 *†
ACE-I/ARB*, n (%) 24,211 (70.1%) 2193 (72.9%) 159 (49.1%) <0.001 *†‡
Statin, n (%) 24,211 (70.1%) 2193 (72.9%) 159 (49.1%) <0.001 *†‡
Other dyslipidaemia
medications, n (%) 2745 (7.9%) 212 (7.1%) 18 (5.6%) 0.12
Oral anticoagulation, n (%) 2425 (7.0%) 226 (7.5%) 33 (10.2%) <0.001 *†‡
Values are n (%) or mean +/− SD, or median (interquartile range). p-values in bold are statistically significant. ACE-I
= angiotensin converting enzyme inhibitors, ARB = angiotensin receptor blockades. * BARC 0 versus BARC 1&2. †
BARC 0 versus BARC 3&5. ‡ BARC 1&2 versus BARC 3&5.
Using multivariable analysis, we identified predictors of cumulative in-hospital and 30-day
MACCE. Cardiogenic shock was the strongest predictor (OR 13.99, 95% Confidence Interval (CI):
11.61–16.86), followed by BARC 3&5 bleeding (OR 4.37, 95% CI: 3.20–5.98) (Figure 1). Other predictors
of cumulative in-hospital and 30-day MACCE included BARC 1&2 bleeding (OR 1.57, 95% CI: 1.33–1.85),
OHCA (OR 2.92, 95% CI: 2.31–3.68), age (OR 1.02, 95% CI: 1.02–1.03), female sex (OR: 1.20, 95% CI:
1.06–1.37), pre-procedural creatinine (OR: 1.002, 95% CI: 1.002–1.003), diabetes (OR 1.22, 95% CI:
1.07–1.39), PVD (OR 1.50, 95% CI: 1.19–1.90), GPI use (OR 1.82, 95% CI: 1.56–2.12), and fibrinolytic
therapy (OR 1.37, 95% CI: 1.03–1.82) (all p < 0.05).
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Baseline characteristics that independently predicted BARC-defined bleeding were older age
(OR 1.02, 95% CI: 1.01–1.02), female sex (OR 1.34, 95% CI: 1.22–1.47), fibrinolytic therapy (OR 1.77, 95%
CI: 1.46–2.15), antiplatelet agents including GPI (OR 1.53, 95% CI: 1.35–1.72) and ticagrelor (OR 1.42,
95% CI: 1.30–1.54), severe NYHA heart failure (defined as LVEF < 30%) (OR 1.26, 95% CI: 1.06–1.49),
cardiogenic shock (OR 1.42, 95% CI: 1.10–1.84), mechanical ventricular support (OR 1.85, 95% CI:
1.32–2.57), and procedural intubation (OR 1.50, 95% CI: 1.12–2.00) (all p < 0.05) (Figure 2). Radial access
(OR: 0.66, 95% CI: 0.61–0.72) was protective against BARC bleeding.
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Figure 3 illustrates yearly rates for mode of vascular access, BARC-defined bleeding, in-hospital
MACCE, and cumulative in-hospital and 30-day MACCE from 2014 to 2017 among STEMI patients and
patients with ACS other than STEMI. Across these four years of VCOR data, there was an observable
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upward trend in uptake of radial access and a decrease in the rate of femoral access. No discernible
trends, however, could be observed in the rates of bleeding and MACCE.
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4. Discussion
In this large, contemporary Australian multicentre registry of an all-comers population undergoing
PCI, the major finding was a stepwise increase in in-hospital MACCE correlating with greater severity
of bleeding: BARC 0 (2.7%), BARC 1&2 (5.6%), and BARC 3&5 (30.9%), as well as 30-day MACCE:
BARC 0 (1.4%), BARC 1&2 (1.8%), and BARC 3&5 (3.1%). Additionally, there were increases in the
length of hospital stay, and risk of rehospitalisation with BARC 3&5 bleeding. Following adjustment of
clinically important variables, clinically significant BARC 3&5 bleeds remained predictive of cumulative
in-hospital and 30-day MACCE (OR 4.37, 95% CI: 3.20–5.98, p < 0.001). Independent predictors of
bleeding included female sex, age, fibrinolytic therapy, and ticagrelor use, while radial access was
associated with a lower risk of bleeding (all p < 0.001).
Rates of major bleeding have been variably defined and variably reported among large, multicentre
PCI studies [18–21]. Kwok et al. conducted a meta-analysis of 42 studies (n = 533,333) that evaluated the
clinical impact of peri-procedural bleeding complications, incorporating various definitions of bleeding,
including TIMI, GUSTO, STEEPLE, HORIZON-AMI, CRUSADE, BARC, and REPLACE-2 [18]. In this
meta-analysis, 1.3% of PCI patients across these studies experienced major bleeding, corroborating our
findings. We investigated VCOR data which utilises the BARC model to define PCI-related bleeding.
The BARC definition was developed in 2010 to enable a standardised and clinically relevant approach
to grading bleeding severity [22]. It is reported to capture a larger number of bleeding events [23]
and informs 1-year prognosis and mortality with greater sensitivity to commonly used bleeding
definitions, including TIMI and REPLACE-2 [22]. The multinational Global Registry of Acute Coronary
Events (GRACE) between 1999 and 2002 reported major bleeding rates of 5.5%, however, only ACS
patients were included [19]. Our study patients, however, reflected a more contemporary, ‘all-comers’
population, and thus, lower risk patients who were undergoing PCI for stable angina and non-ACS
indications were also included. Studies which have analysed similar all-comers populations, including
the CathPCI registry between 2004 and 2011 (n = 3,386,688) and the prospective ADAPT-DES trial
(n = 8582), reported that 1.7% and 1% of patients experienced major bleeding respectively, which are
congruent with our findings [20,21].
Rates of adverse in-hospital and 30-day outcomes in our study, especially mortality and MACCE,
were similarly observed in analyses of other large registries including CathPCI [20,24], the British
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Cardiovascular Intervention Society (BCIS) [18,25], and the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) [18,25]. The rate of in-hospital mortality in patients enrolled in CathPCI
between 2004 and 2011 was 2.5%, and 30-day MACE in patients ≥ 65 years old between 2004 and
2008 was 5.7%, similar to our findings as well as those from studies analysing the SCAAR and BCIS
registries [18,20,24,25]. However, we evaluated a more contemporary population as evident with
changes to ACS management over time, including PCI techniques such as radial access. Uptake of
radial access was 51.5% in our study, compared to 41–45% and 46% among the BCIS and SCAAR
datasets, respectively. The rates of both in-hospital and 30-day mortality and MACCE were significantly
higher among patients who experienced greater severity of bleeding in our study. In the meta-analysis
by Kwok et al., 17.3% of patients who had major bleeding experienced MACE, compared to 5.4% of
patients who experienced no bleeding complications [18]. Our study findings add to the existing body
of evidence which collectively underscore the correlation between increasing severity of PCI-related
bleeding and poor clinical outcomes, including MACCE but also increased length of hospital stay and
risk of rehospitalisation.
In our study, major bleeding was an independent predictor of cumulative in-hospital and
30-day MACCE (OR = 4.4) after adjusting for clinically important variables including age, sex, BMI,
diabetes, PVD, pre-procedural creatinine, OHCA, cardiogenic shock, mode of vascular access, GPI,
and fibrinolytic therapy. The independent adverse impact of PCI-related bleeding on clinical outcomes
has been consistently reported in numerous studies [1–3,18–20,26]. Kwok et al. showed that major
bleeding after PCI was independently associated with a 3-fold increase in mortality and MACE,
and this was maintained at one year [3,18]. This is similar to the findings of US-based all-comers
registries, including CathPCI [20,24] and the cardiac catheterization database [27], as well as the
prospective ADAPT-DES trial which found that patients, across 11 sites in the US and Germany, were
3.4-fold more likely to experience MACE outcomes if they experienced bleeding with an associated
decrease in haemoglobin (∆Hgb) ≥ 4 g/Dl [21]. Our study substantiates the current state of literature
that underscore the impact of bleeding on adverse outcomes with relevance to contemporary, local
Australian practice. Collectively, this highlights the need for strategies to address bleeding and mitigate
bleeding consequences.
Fibrinolytic therapy and GPI use were also predictive of cumulative in-hospital and 30-day MACCE,
independent of clinically important variables, including bleeding. In contemporary Australian practice,
these agents are predominantly used in high-risk patients, which could explain the additive effect of
GPI and fibrinolysis use on MACCE. Intravenous GPI is often administered in patients with high-risk
clinical or angiographic characteristics (e.g., with those with large thrombus burden), and fibrinolytic
therapy is commonly used when there is delay in primary PCI, or if the patient is not at a PCI-capable
centre [28]. However, both fibrinolysis and GPI increase bleeding risk in patients undergoing PCI due to
their mechanism of action and might well contribute to the MACCE rates through potentiating bleeding.
Currently, aspirin and P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel) are the
recommended antiplatelet treatment for patients during and after PCI, with studies showing significant
reduction to 30-day MACE compared to aspirin alone (p = 0.0001) [29]. Patients who have mechanical
heart valves or atrial fibrillation will also require additional oral anticoagulation, which increases
bleeding risk further [30]. Indeed, ticagrelor use in our study independently predicted major bleeding
(OR 1.42). A downtrend in the use of clopidogrel has been reported in patients enrolled in the
Melbourne Interventional Group (MIG) registry (2009–2013), with the uptake of ticagrelor at 45% as
the dominant P2Y12 inhibitor of choice by the latter half of 2013 [31]. All these studies collectively
highlight the link between the efficacy of antiplatelet agents in preventing recurrent thrombosis and
ischaemic sequelae, with balancing bleeding risk related to the efficacy of the antiplatelet therapy.
A contemporary initiative by the Academic Research Consortium for High Bleeding Risk (ARC-HBR),
in 2019, provided a framework to stratify PCI patients with high bleeding risk [32]. A tailored approach
for high-bleeding risk patients with judicious efforts to minimise the use of potent antiplatelet agents
among older age patients, female sex, and low BMI may mitigate bleeding consequences.
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The potential mechanisms by which major bleeding might increase mortality and MACCE
are likely multifactorial. Some studies suggest that the frequent cessation of anti-thrombotic or
antiplatelet therapy among patients who experience major bleeding, could subsequently increase
their risk of ischaemic events [18,26,33]. In our study, patients who experienced major bleeding were
prescribed fewer antiplatelet agents at discharge, including aspirin, thienopyridine, and ticagrelor (all
p < 0.001). Anaemia is known to independently predict adverse outcomes in patients undergoing
PCI [26,34,35]. This could be through the deleterious effect of blood transfusions [34], or the endogenous
production of erythropoietin in response to anaemia, manifesting clinically as increased risk of stroke,
MI, and mortality among STEMI patients [35,36]. There may also be short-term haemodynamic
consequences of anaemia through tachycardia, hypotension, and congestive cardiac failure, all of
which can increase myocardial oxygen demand [26].
In our analysis, femoral vascular access predicted major bleeding (OR 1.52, 95% CI: 1.39–1.64),
substantiating the results of numerous prior studies [1,4–8]. In particular, the meta-analysis by Ferrante
et al. analysed 24 studies, including MATRIX and RIVAL, and underscored that PCI with femoral access
was associated with increased risk of major bleeding compared to radial access, particularly among
ACS patients [6]. In the 2018 European Guidelines, radial access was a class I recommendation among
patients with ACS undergoing PCI [37]. This is unless there are overriding procedural considerations,
including the operator’s expertise with radial access. In our study, while femoral access did not
independently predict cumulative in-hospital and 30-day MACCE, this could be explained in part by
the effect of other stronger variables on MACCE, including BARC 3&5 bleeding, cardiogenic shock,
and OHCA.
Interestingly, while the uptake of femoral access has significantly decreased since 2014, the rate of
major bleeding, as well as in-hospital and 30-day outcomes, have not changed appreciably. Similar
trends were noted in the MIG registry between 2005 and 2016 [38]. A potential reason for the lack of
improvement in 30-day mortality and adverse outcomes, highlighted by Biswas et al., is that 30 days
may be too short a time frame to observe a mortality benefit as a result of procedural changes to PCI
techniques [38]. Additionally, as noted above, other stronger predictors than vascular access would
likely have had a major effect on 30-day outcomes.
However, our study findings add to the body of literature emphasising the importance and
adverse impact of bleeding on clinical outcomes. Any bleeding portends an adverse effect on
outcome. These findings underscore the need for strategies to minimise bleeding, including adoption
of radial access for PCI procedures and also meticulous care with prescription of antiplatelet and
anticoagulant combination therapy among high-risk patients, such as those of older age, females, low
BMI, and patients with severe heart failure.
Our study results should be interpreted in the context of several limitations, including its
retrospective design and observational nature. Firstly, due to the large number of variables being
compared between the different BARC categories of bleeding, the results and p-values presented
in the univariate analysis should be interpreted with caution and regarded as hypothesis-generating
because of the confounding effect of multiple testing. However, the data provide trends in patient
and procedural characteristics across increasing severity of BARC bleeding. Secondly, there were
likely additional confounding variables that were not measured or could not be measured which
could impact clinical outcomes. Thirdly, BARC 0 and BARC 1&2 complications might have been
underreported as these frequently did not require hospital-based intervention. Fourthly, patients who
had CABG surgery without BARC 4 bleeds were not excluded, which might have affected 30-day
MACCE outcomes. Fifthly, the timing of occurrence of any bleeding event in relation to development
of in-hospital or 30-day MACCE was not individually verified or adjudicated given that VCOR is
a state-wide database and the large number of clinical and bleeding events. Sixthly, VCOR also
does not capture non-access site bleeding and severity of non-access site bleeds, which could have
adversely impacted on outcomes. Finally, the follow-up duration of 30 days in our study was short,
and longer-term follow-up may be necessary in order to ascertain significant differences in rates
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of adverse outcomes with contemporary procedural changes, including radial access and dynamic
changes to antiplatelet and anticoagulant regimens.
5. Conclusions
Bleeding, especially major bleeding, is uncommon (~1%) in contemporary PCI practice.
However, major bleeding is independently predictive of in-hospital and 30-day MACCE. With
increasing severity of bleeding, there were also stepwise increases in in-hospital and 30-day mortality,
length of hospital stay, and rehospitalisation. Efforts to mitigate bleeding and its consequences may
improve patient morbidity and mortality.
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Appendix A
Table A1. Bleeding Academic Research Consortium (BARC) definition of PCI-related bleeding [11].
Type Definition
0 No bleeding
1
Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of
studies, hospitalisation, or treatment by a healthcare professional. May include episodes leading to
self-discontinuation of medical therapy by the patient without consulting a healthcare professional
2
Any overt, actionable sign of haemorrhage (e.g., more bleeding than would be expected for a
clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for
type 3, 4, or 5, but does meet at least one of the following criteria: (1) requiring nonsurgical,
medical intervention by a healthcare professional, (2) leading to hospitalisation or increased level
of care, or (3) prompting evaluation
3 a
- Overt bleeding plus haemoglobin drop of 3 to <5 g/dL (provided haemoglobin drop is related
to bleed)
- Any transfusion with overt bleeding
3 b
- Overt bleeding plus haemoglobin drop ≥5 g/dL (provided haemoglobin drop is related
to bleed)
- Cardiac tamponade
- Bleeding requiring surgical intervention for control (excluding
dental/nasal/skin/haemorrhoid)
- Bleeding requiring intravenous vasoactive agents
3 c
- Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation,
does include intraspinal)
- Subcategories confirmed by autopsy, imaging, or lumbar puncture
- Intraocular bleed compromising vision
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Table A1. Cont.
Type Definition
4
- CABG-related bleeding:
- Perioperative intracranial bleeding within 48 h
- Reoperation after closure of sternotomy for the purpose of controlling bleeding
- Transfusion of ≥5 U whole blood or packed red blood cells within a 48 h period
- Chest tube output ≥ 2 L within a 24 h period
5 a Probable fatal bleeding: no autopsy or imaging confirmation but clinically suspicious
5 b Definite fatal bleeding: overt bleeding or autopsy or imaging confirmation
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